Neurocrine Biosciences (NBIX) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: $790 million, a 28% year-over-year increase.

INGREZZA Sales: $687 million, marking a record with double-digit growth and strong new patient additions.

CRENESSITY Sales: $98 million, reflecting strong early adoption with 80% of prescriptions reimbursed.

Cash Position: Over $2.1 billion, with no debt.

SG&A Expense Increase: Anticipated increase of approximately $150 million in 2026 due to sales force expansions.

2Strategic Updates and Business Highlights

Sales Force Expansion: Plans to expand the sales force for both INGREZZA and CRENESSITY to enhance market penetration and patient access.

Clinical Pipeline: Progress in Phase III studies for osavampator (major depressive disorder) and direclidine (schizophrenia). Initiation of 4 new Phase I studies and 2 Phase II studies expected.

CRENESSITY Launch: Positioned as a first-in-class therapy for congenital adrenal hyperplasia (CAH), with ongoing efforts to establish it as the standard of care.

Market Opportunity: INGREZZA continues to target the tardive dyskinesia (TD) market, with only 10% of diagnosed patients currently treated.

3Forward Guidance and Outlook

Q4 Expectations: Anticipated sequential growth of $15 million to $20 million, adjusting for a 14-week ordering dynamic in Q3.

Long-term Growth: Confidence in sustained growth driven by strong market demand and strategic investments in sales and R&D.

2026 Projections: Continued strong performance expected, with a focus on maximizing patient share before the potential impacts of the Inflation Reduction Act (IRA).

4Bad News, Challenges, or Points of Concern

DOJ Investigation: Ongoing investigation regarding sales and marketing practices for INGREZZA, with Neurocrine cooperating fully.

IRA Impacts: Concerns about potential pricing pressures and market dynamics as competitors navigate the IRA, although INGREZZA's patient retention is expected to mitigate some risks.

Seasonality in CRENESSITY: Questions raised about potential seasonal impacts on new patient starts, though management indicated no significant seasonality expected.

5Notable Q&A Insights

CRENESSITY Adoption: Q3 saw 540 new patient starts, with management optimistic about continued growth despite a slight decline from Q2.

Reimbursement Dynamics: Strong reimbursement rates for CRENESSITY, with 90% of patients receiving approval, alleviating initial concerns about access.

Sales Force Strategy: The integration of psychiatry and neurology teams aims to streamline efforts and capitalize on growth opportunities in both segments.

Market Share Insights: Neurocrine is gaining a majority of new patient starts in the VMAT2 market, indicating strong competitive positioning against AUSTEDO. Overall, Neurocrine Biosciences reported a robust Q3 2025 performance, driven by strong sales growth and strategic initiatives, while also navigating challenges related to regulatory scrutiny and market dynamics.